

*neoformans* was also demonstrated in the solid-phase disk diffusion assay, and fungicidal activity confirmed in killing kinetics experiments. Broth macrodilution minimum inhibitory and minimum fungicidal concentrations for the most potent modification ranged from 0.0975-1.56 µg/ml and 0.0975-6.24 µg/ml, respectively. The minimum inhibitory concentrations were nearly identical in the presence of human serum, but increased with lowered pH.---

Amend the claims as follows:

Claim 1, cancel line 1 and substitute ---a method of inhibiting fungal growth in a host---;

line 2, cancel “a pharmaceutically” and substitute --- an ---;

line 3, after “and” insert ---an ---;

same line, cancel “an active ingredient” and substitute --- a compound---;

line 4, cancel “the following chemical structures.” and substitute ---  
formulae 1a, 1b, 1c, 1d and 1e, wherein the structures of said formulae are as follows: ---;

after structures 1a, 1b, 1c, insert a semicolon ---;---

after structure 1d, insert ---; and ---

after structure 1e, insert a period ---.---

Claim 2, line 1, cancel “is” and substitute --- are---.

Claim 3, line 2, cancel “Cryptococcus” and substitute ---cryptococcosis---;

Claims 4, 5, 6 and 7, line 1, cancel “3” and substitute ---9 ---.

Claim 8, line 1, cancel “active ingredient is”;

cancel line 2 and substitute ---carrier comprises a water-and-oil emulsion, petrolatum---;

Add the following claims:

--- 9. The method according to claim 3 wherein said host is a mammal.---

---10. The method according to claim 9 in which said mammal is a human.---

---11. The method according to claim 10 in which said active ingredient is administered to said host by parenteral means.---

---12. The method according to claim 10 in which said active ingredient is administered topically to said host.---

---13. The method according to claim 10 in which said active ingredient is administered intravenously to said host.---

---14. The method according to claim 10 in which said active ingredient is administered in a suppository inserted in said host.---

---15. The method according to claim 12 in which said carrier comprises a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, a solubilizer and fragrance.---

#### REMARKS

Claims 1-8 are in the application as filed. Of these claims 1-8 have been amended and claims 9-15 have been added. Claims 1-15 are in the case and in issue.

There appears to be some confusion in this application in that there is both a US provisional application and a PCT application for this case, assuming the Examiner is dealing with the PCT, two criticisms of the application are not completely understood. The references to "missing" "Brief Description of the Drawings" and the "Abstract" identify pages which were in the application as filed (See pages 5 and 22, attached). However, the PCT required different language which is being amended herewith to comply with the Examiner's request. The ABSTRACT from the provisional has also been added by this amendment, however, it was included with the original PCT filing and